Motley Fool: 5 Top Pharmaceutical Stocks to Buy in 2019

More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that’s expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS). With so much money being spent on necessary medicines,…

Advertisements

Motley Fool: 4 Blockbuster Drug Launches to Watch in 2019

Get ready for some blockbuster drug launches that could get intense.  Clarivate Analytics has offered a report on experimental drugs entering the market soon that are expected to generate sales above $1 billion in 2023. Every potential blockbuster is important to…

Motley Fool: 3 Top Biotech Stocks to Buy in October

If Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corporation (NASDAQ:INCY), and AbbVie Inc. (NYSE:ABBV) aren’t on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and…

Motley Fool: Here's Why Antares Pharma Jumped Higher Today

What happened Shares of Antares Pharma (NASDAQ:ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted. The approval comes about a year after Antares disclosed that the FDA…